Both Mammoth’s therapies and diagnostics will be based on what the company touts as the largest toolbox of CRISPR proteins on earth. Through the financing, Mammoth plans to expand the toolbox and broaden its pipeline of genome-edited therapies, focusing on the smallest known CRISPR systems, based on Cas14, which targets single-stranded DNA; and Casɸ, which is encoded exclusively in the genomes of huge bacteriophages . . .
The post Mammoth Valuation: Unicorn Eyes In Vivo CRISPR Drugs, Diagnostics appeared first on GEN – Genetic Engineering and Biotechnology News.